Clinical Trials Logo

Clinical Trial Summary

This is a phase II, multicenter, single-arm, open-label safety and efficacy study of bavituximab in combination with carboplatin plus paclitaxel in patients with locally advanced or metastatic breast cancer.


Clinical Trial Description

n/a


Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00669565
Study type Interventional
Source Peregrine Pharmaceuticals
Contact
Status Completed
Phase Phase 2
Start date July 2008
Completion date August 2010

See also
  Status Clinical Trial Phase
Completed NCT03511781 - Palliative Hypofractionated Radiotherapy in Advanced Incurable Breast Cancer N/A
Completed NCT00199212 - PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2 Phase 1
Recruiting NCT06281860 - Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration Phase 1
Active, not recruiting NCT02755272 - A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer Phase 2
Withdrawn NCT02140437 - Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC Phase 2
Terminated NCT02183805 - Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer Phase 2
Terminated NCT01531764 - BIBW 2992 (Afatinib) and Vinorelbine Phase 2
Completed NCT01631552 - Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer Phase 1/Phase 2
Withdrawn NCT01906112 - Role of Surgery for the Primary in Patients With Breast Cancer Stage IV. Phase 3
Recruiting NCT02161315 - Steroid Aromatase Inhibitors Versus Progestogens for nSAID-resistanced Late Stage Breast Cancer N/A
Completed NCT00433095 - Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer Phase 2